TIMP4 and neoplasm: In clinical studies, the overexpression of TIMP-1 and TIMP-4 has been associated with a poorer prognosis in many tumours; they activate signalling pathways related to inflammation and fibrosis—for example, mitogen-activated protein kinase (MAPK) pathways [44].